The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Subscribe To Our Newsletter & Stay Updated
